Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Immatics N.V.    IMTX   NL0015285941

IMMATICS N.V.

(IMTX)
  Report
Delayed Quote. Delayed Nasdaq - 01/26 04:00:00 pm
10.87 USD   -2.69%
01/06IMMATICS N : Corporate Presentation, January 2021
PU
2020Immatics Reports Wider Loss, Higher Revenue in Q3
MT
2020PRESS RELEASE : Immatics Announces Third Quarter -4-
DJ
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immatics N : Corporate Presentation, October 2020

09/29/2020 | 07:25am EST

Immatics

Corporate Presentation, October 2020

© 2020 Immatics. Not for further reproduction or distribution.

Forward Looking Statement

This presentation ("Presentation") is provided by Immatics N.V. ("Immatics" or the "Company") for informational purposes only. The information contained herein does not purport to be all-inclusive and Immatics nor any of its affiliates nor any of its or their control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this presentation, you confirm that you are not relying upon the information contained herein to make any decision.

Forward-Looking Statements. Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company's future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, the IND filing for IMA204, IMA301, IMA401, the Company's focus on partnerships to advance its strategy, projections of future cash on hand and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company's filings with the Securities and Exchange Commission (SEC). Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Company undertakes no duty to update these forward-looking statements.

No Offer or Solicitation. This communication is for informational purposes only and does not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, and there shall be no sale of securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Certain information contained in this Presentation relates to or is based on studies, publications, surveys and the Company's own internal estimates and research. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its internal research is reliable, such research has not been verified by any independent source. This meeting and any information communicated at this meeting are strictly confidential and should not be discussed outside your organization.

2

Key Elements to Build a Global Leader in TCR-based Immunotherapies

Immatics' proprietary platforms create a leadership position in the TCR therapeutics space

  • Two highly differentiated technology platforms for the discovery of pHLA targets & T cell receptors

Foundation to achieve the next advance in immunotherapy, particularly for solid tumors

  • Platforms validated by multiple strategic collaborations with oncology-focused global leaders incl. Amgen, Genmab, BMS, GSK and MD Anderson Cancer Center

Immatics is advancing a proprietary pipeline of Adoptive Cell Therapies (ACT) & TCR Bispecifics

Four ACT programs in clinical development covering a broad range of solid cancers

Two TCR Bispecifics programs with off-the-shelf availability in advanced preclinical development

  • Next-Generationpersonalized multi-target approach designed to achieve durable clinical responses

Immatics builds on sustainable fundamentals

Strong IP estate & worldwide rights retained on lead programs

  • Approx. $320m of cash on the balance sheet post NASDAQ debut and a cash runway of 3+ years
  • Supported by a strong shareholder base of premier US and European shareholders

3

Developing Targeted Therapeutics to Patients with Solid Cancers

… in whom Current Immunotherapies Have Limited Efficacy

Most cancer patients do not benefit from current immuno-oncology approaches

Checkpoint inhibitors

Clinical benefit mainly in patients with tumors with high mutational burden minority of all cancers*

CAR-T

Clinical benefit mainly in patients with hematological indications minority of all cancers**

Immatics is turning limitations into opportunities by

Developing TCR-based immunotherapies with the aim to offer a targeted therapy to patients with high medical need

*Chalmers et al., 2017 **SEER Cancer Statistics Review, 1975-2017, Estimated New Cancer Cases for 2020

4

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Immatics NV published this content on 29 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 September 2020 11:24:01 UTC


© Publicnow 2020
All news about IMMATICS N.V.
01/06IMMATICS N : Corporate Presentation, January 2021
PU
2020Immatics Reports Wider Loss, Higher Revenue in Q3
MT
2020PRESS RELEASE : Immatics Announces Third Quarter -4-
DJ
2020PRESS RELEASE : Immatics Announces Third Quarter -3-
DJ
2020PRESS RELEASE : Immatics Announces Third Quarter -2-
DJ
2020PRESS RELEASE : Immatics Announces Third Quarter 2020 Financial Results and Busi..
DJ
2020BofA Securities Starts Immatics at Buy With $13 Price Target
MT
2020IMMATICS N : Factsheet English
PU
2020IMMATICS N : ACTolog® IMA101 Phase-1-Data at the 35th Annual SITC conference
PU
2020Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 ..
GL
More news
Financials (USD)
Sales 2020 35,6 M - -
Net income 2020 -275 M - -
Net cash 2020 278 M - -
P/E ratio 2020 -1,73x
Yield 2020 -
Capitalization 684 M 684 M -
EV / Sales 2020 11,4x
EV / Sales 2021 13,5x
Nbr of Employees 230
Free-Float 54,7%
Chart IMMATICS N.V.
Duration : Period :
Immatics N.V. Technical Analysis Chart | IMTX | NL0015285941 | MarketScreener
Technical analysis trends IMMATICS N.V.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 17,40 $
Last Close Price 10,87 $
Spread / Highest target 158%
Spread / Average Target 60,1%
Spread / Lowest Target 19,6%
EPS Revisions
Managers and Directors
NameTitle
Harpreet Singh-Jasuja Chief Executive Officer & Managing Director
Peter Alan Chambré Chairman-Supervisory Board
Arnd Christ Chief Financial Officer
Cedrik M. Britten Chief Medical Officer
Steffen Walter Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
IMMATICS N.V.0.74%684
MODERNA, INC.45.35%58 169
LONZA GROUP AG6.79%50 766
CELLTRION, INC.-10.58%39 697
IQVIA HOLDINGS INC.0.65%35 090
SEAGEN INC.-1.43%32 583